venadaparib (NOV 1401)

News alerts, weekly reports and conference planners

Company:

Ildong, National OncoVenture

Drug class:

PARP inhibitor

Related drugs:

BRCA2 mutation	Breast Cancer	BRCA2 mutation	Breast Cancer	NOV 1401 Sensitive: C3 – Early Trials NOV 1401 Sensitive : C3	NOV 1401 Sensitive: C3 – Early Trials NOV 1401 Sensitive : C3
BRCA1 mutation	Breast Cancer	BRCA1 mutation	Breast Cancer	NOV 1401 Sensitive: C3 – Early Trials NOV 1401 Sensitive : C3	NOV 1401 Sensitive: C3 – Early Trials NOV 1401 Sensitive : C3
ASXL1 mutation + ATM mutation	Pancreatic Cancer	ASXL1 mutation + ATM mutation	Pancreatic Cancer	NOV 1401 Sensitive: C3 – Early Trials NOV 1401 Sensitive : C3	NOV 1401 Sensitive: C3 – Early Trials NOV 1401 Sensitive : C3

Associations
(3)